Is kisspeptin-10 FDA-approved, and what does the research show?

What is kisspeptin-10?

Kisspeptin is a hormone made in the hypothalamus, the part of the brain that runs the hormone system behind puberty, fertility and sex hormones ¹. The body cuts the parent protein into pieces of different lengths, named by their number of amino acids: kisspeptin-54, -14, -13 and -10 ¹. Kisspeptin-10 is the shortest, and every form shares its ten-amino-acid tail, the part that binds the kisspeptin receptor ¹. It clears fast: its half-life, the time for half of it to leave the blood, is about three minutes against 28 minutes for kisspeptin-54 ¹. FDA describes the compounded substance as "a synthetic peptide consisting of ten amino acids" ².

Is kisspeptin-10 FDA-approved?

Kisspeptin-10 is not FDA-approved: Drugs@FDA lists no approved kisspeptin product as of November 9, 2026 ³. FDA's own review for its compounding advisory committee states that "there is no approved product in any country containing kisspeptin-10 at this time" ². It is a research compound, given in short hormone studies ¹, ⁵.

A pharmacy nominated kisspeptin-10 for FDA's 503A bulks list, the list of substances that licensed pharmacies may compound ². FDA has placed it in Category 2 of its nominations list, updated May 14, 2026, under the heading "Bulk Drug Substances that Raise Significant Safety Risks" ⁴. FDA explains that "bulk drug substances that may present significant safety risks have been placed in category 2 under the interim policies" ⁹.

In October 2024 FDA's reviewers told the Pharmacy Compounding Advisory Committee that the criteria "weigh against" adding kisspeptin-10 to the list ². The committee is FDA's outside advisory panel on compounding ¹⁰. It voted 11 to 0 against adding it to the list ¹⁰. Its minutes record that it "unanimously agreed that Kisspeptin-10 should not be included on the 503A Bulks List due to the lack of convincing safety and efficacy data" ¹⁰. As of May 14, 2026, kisspeptin-10 still sits in Category 2 on FDA's list ⁴.

See the FDA status of every peptide, updated weekly.

How does kisspeptin-10 work?

Kisspeptin binds a receptor on the brain cells that release gonadotropin-releasing hormone, or GnRH, the signal that starts the reproductive hormone cascade ¹. GnRH prompts the pituitary gland to release luteinizing hormone, LH, and in men LH drives testosterone production ¹, ⁵. Studied in people: in healthy men, a single dose of kisspeptin-10 into a vein set off an LH pulse within minutes ¹. The pulse was 2.4 times the size of the men's own ¹.

The effect fades under continuous exposure: in monkeys, a steady infusion of kisspeptin-10 peaked at three hours and had fallen away by twelve ¹. FDA calls this tachyphylaxis and notes it "can develop when kisspeptin-10 is administered uninterruptedly for a long period" ². In women, kisspeptin's effect on LH varies with the phase of the menstrual cycle ¹. In healthy men kisspeptin reset the timing of the GnRH pulse generator; in women it did not ¹.

What does the research show?

Studied in people with kisspeptin-10 itself: a proof-of-concept study published in 2013 ⁵. It enrolled five men with type 2 diabetes and low testosterone and seven healthy men of matched age ⁵. A single dose into a vein raised LH in both groups by a similar amount ⁵. Four of the men with diabetes received an 11-hour infusion ⁵. Their average LH climbed from 3.9 to 20.7 IU/L, and their average testosterone rose by about a third, from 8.5 to 11.4 nmol/L in the study's units ⁵.

The study measured hormone levels and reported no symptom outcomes ⁵. FDA's reviewers found "insufficient evidence to make a conclusion on the effectiveness of kisspeptin-10" for men with secondary hypogonadism, low testosterone from a failed signal in the brain or pituitary ². They cite "the small number of subjects" and the studies' "exploratory nature" ².

Studied in people with kisspeptin-54, the longer form: two randomized, double-blind, placebo-controlled crossover trials by one research group, reported in three papers ⁶, ⁷, ⁸. Each was built around a 75-minute infusion into a vein ⁶, ⁷, ⁸. In 29 healthy young men, kisspeptin increased activity in limbic brain regions, the brain's emotion circuits, in response to sexual and couple-bonding images ⁶. It also reduced negative mood and did not raise testosterone during the scan ⁶. In the same 29 men, scanned at rest, the change kisspeptin made to a resting brain network went with lower sexual-aversion scores on questionnaires ⁷.

In premenopausal women with hypoactive sexual desire disorder, 40 were randomized and 32 completed both visits ⁸. Kisspeptin changed brain responses to erotic videos and to attractive faces ⁸. On the questionnaires, an exploratory item, "How sexy do you feel right now?", rose by 0.5 points (95% confidence interval 0.05 to 0.95) ⁸. The trial's primary outcome was the brain signal during the infusion, not desire over weeks of treatment ⁸.

What has not been studied: FDA found "no published clinical trials" that "assessed the safety of kisspeptin-10 when administered chronically or on a fixed schedule for over one day" ². No published trial of kisspeptin-10 for sexual desire, weight or fertility outcomes was found as of November 9, 2026.

What are the side effects?

In the trial in women with hypoactive sexual desire disorder, kisspeptin-54 "was well-tolerated with no reported adverse effects" ⁸. The two brain-imaging studies in men do not report adverse-event data ⁶, ⁷. For kisspeptin-10 itself, FDA's reviewers summarized the published studies: "No serious adverse events were reported in these studies. However, these studies were of short duration, had small sample sizes, and often did not include information on adverse events" ².

FDA's adverse-event reporting system held one kisspeptin-10 report through October 25, 2023 ². A 17-year-old with hypogonadotropic hypogonadism, FDA's other name for secondary hypogonadism, was given a compounded kisspeptin-10 injection daily for six weeks to stimulate testosterone ². He gained weight and his estrone, a form of estrogen, rose; FDA calls the case "limited by an unclear temporal relationship and insufficient information" ². In animal work FDA also notes "pro-atherosclerotic effects of kisspeptin-10" whose "clinical relevance remains unclear" ².

FDA's own safety words sit on its Category 2 page, current as of April 22, 2026 ⁹. Compounded kisspeptin-10 "may pose risk for immunogenicity for certain routes of administration," and "the agency lacks sufficient information to know whether the drug would cause harm when administered to humans" ⁹. Immunogenicity means the body mounting an immune response against the peptide. FDA writes that the consequences "may range from antibody responses with no apparent clinical manifestations to life-threatening and catastrophic reactions" ². The risk, FDA says, is higher for a peptide given by injection under the skin than into a vein ².

In sport

WADA, the World Anti-Doping Agency, names "kisspeptin and its agonist analogues" on its 2026 Prohibited List under S2.2.1, "Testosterone-stimulating peptides in males" ¹¹. Class S2, peptide hormones, growth factors, related substances and mimetics, is prohibited at all times, in and out of competition ¹¹. The list's M2.2 separately prohibits "Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations" ¹¹.

What JumpstartMD offers

JumpstartMD does not prescribe kisspeptin-10. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 9, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.